TY  - JOUR
AU  - Hasche, Daniel
AU  - Ahmels, Melinda
AU  - Braspenning-Wesch, Ilona
AU  - Stephan, Sonja
AU  - Cao, Rui
AU  - Schmidt, Gabriele
AU  - Müller, Martin
AU  - Rösl, Frank
TI  - Isoforms of the Papillomavirus Major Capsid Protein Differ in Their Ability to Block Viral Spread and Tumor Formation.
JO  - Frontiers in immunology
VL  - 13
SN  - 1664-3224
CY  - Lausanne
PB  - Frontiers Media
M1  - DKFZ-2022-00622
SP  - 811094
PY  - 2022
N1  - #EA:F030#LA:F030#
AB  - Notably, the majority of papillomaviruses associated with a high cancer risk have the potential to translate different isoforms of the L1 major capsid protein. In an infection model, the cutaneous Mastomys natalensis papillomavirus (MnPV) circumvents the humoral immune response of its natural host by first expressing a 30 amino acid extended L1 isoform (L1LONG). Although inducing a robust seroconversion, the raised antibodies are not neutralizing in vitro. In contrast, neutralizing antibodies induced by the capsid-forming isoform (L1SHORT) appear delayed by several months. We now provide evidence that, although L1LONG vaccination showed a strong seroconversion, these antibodies were not protective. As a consequence, virus-free animals subsequently infected with MnPV still accumulated high numbers of transcriptionally active viral genomes, ultimately leading to skin tumor formation. In contrast, vaccination with L1SHORT was completely protective. This shows that papillomavirus L1LONG expression is a unique strategy to escape from antiviral immune surveillance.
KW  - Mastomys coucha (Other)
KW  - NMSC (non-melanoma skin cancer) (Other)
KW  - cutaneous papillomaviruses (Other)
KW  - immune escape mechanism (Other)
KW  - major capsid protein (L1) (Other)
KW  - neutralizing antibodies (Other)
KW  - vaccination (Other)
KW  - viral infection (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:35359995
C2  - pmc:PMC8964102
DO  - DOI:10.3389/fimmu.2022.811094
UR  - https://inrepo02.dkfz.de/record/179371
ER  -